Lundbeck to utilize fast-track status in Alzheimer's drug dialog with FDA
Lundbeck CEO Deborah Dunsire announces that preparations for an FDA application are underway, and the US is not the only market the company is eyeing for its agitation candidate brexpiprazol. Promising data on the drug was publicized on Monday morning.
by marketwire, translated by catherine brett
Pharmaceutical company Lundbeck is naturally very pleased with the positive topline data the firm and its partner Otsuka Pharmaceuticals released for its candidate brexpiprazol on Monday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck lawyer says pharma is fighting over legal talent
For subscribers
